

# Masashi Takano

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/917392/publications.pdf>

Version: 2024-02-01

102  
papers

2,411  
citations

201674

27  
h-index

223800

46  
g-index

107  
all docs

107  
docs citations

107  
times ranked

3318  
citing authors

#	ARTICLE	IF	CITATIONS
1	Clear cell carcinoma of the endometrium. <i>Gynecologic Oncology</i> , 2022, 164, 658-666.	1.4	23
2	Comparison of clinical behavior between mucinous ovarian carcinoma with infiltrative and expansile invasion and high-grade serous ovarian carcinoma: a retrospective analysis. <i>Diagnostic Pathology</i> , 2022, 17, 12.	2.0	3
3	Clinical significance of CD8 <sup>+</sup> positive lymphocytes on tumor cell clusters of ascites cell block in ovarian high-grade serous carcinoma. <i>Cancer Medicine</i> , 2022, 11, 2085-2095.	2.8	3
4	Potential efficacy of weekly low-dose administration of bevacizumab as a combination therapy for platinum-resistant ovarian carcinoma: a retrospective analysis. <i>BMC Cancer</i> , 2022, 22, 176.	2.6	2
5	Randomized phase III trial comparing pegylated liposomal doxorubicin (PLD) at 50 mg/m <sup>2</sup> versus 40 mg/m <sup>2</sup> in patients with platinum-refractory and -resistant ovarian carcinoma: the JGOG 3018 Trial. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e9.	2.2	5
6	Survival and biomarker analysis for ovarian mucinous carcinoma according to invasive patterns: retrospective analysis and review literature. <i>Journal of Ovarian Research</i> , 2021, 14, 33.	3.0	13
7	Criteria for placenta accreta spectrum in the International Federation of Gynaecology and Obstetrics classification, and topographic invasion area are associated with massive hemorrhage in patients with placenta previa. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2021, 100, 1019-1025.	2.8	8
8	Significance of mesothelin and CA125 expression in endometrial carcinoma: a retrospective analysis. <i>Diagnostic Pathology</i> , 2021, 16, 28.	2.0	11
9	On-tissue polysulfide visualization by surface-enhanced Raman spectroscopy benefits patients with ovarian cancer to predict post-operative chemosensitivity. <i>Redox Biology</i> , 2021, 41, 101926.	9.0	20
10	MicroRNA-21 expression in cancer cells is an independent biomarker of progression-free survival of endometrioid endometrial carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 479, 883-891.	2.8	5
11	Psoas muscle index at the fifth lumbar vertebra as a predictor of survival in epithelial ovarian cancers. <i>Molecular and Clinical Oncology</i> , 2021, 15, 177.	1.0	10
12	Uterine serous carcinoma. <i>Gynecologic Oncology</i> , 2021, 162, 226-234.	1.4	58
13	Resuscitative efficacy of hemoglobin vesicles for severe postpartum hemorrhage in pregnant rabbits. <i>Scientific Reports</i> , 2021, 11, 22367.	3.3	2
14	Management of patients with atypical glandular cell cytology at our hospital. <i>The Journal of the Japanese Society of Clinical Cytology</i> , 2021, 60, 311-316.	0.0	0
15	Different Prognostic Implications of Aquaporin-1 and Aquaporin-5 Expression among Different Histological Types of Ovarian Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 263-271.	1.9	10
16	Co-Expression of Mesothelin and CA125 Is Associated with the Poor Prognosis of Endometrial Serous Carcinoma and Mixed Carcinomas Including Serous Carcinoma. <i>Pathology and Oncology Research</i> , 2020, 26, 2299-2306.	1.9	9
17	Aquaporin 3 Expression in Endometrioid Carcinoma of the Uterine Body Correlated With Early Stage and Lower Grade. <i>Pathology and Oncology Research</i> , 2020, 26, 2247-2253.	1.9	5
18	The use of magnetic resonance imaging to predict placenta previa with placenta accreta spectrum. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2020, 99, 1657-1665.	2.8	10

#	ARTICLE	IF	CITATIONS
19	Correlation of high LAT1 expression with the prognosis of endometrioid carcinoma of the uterine corpus. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2020, 477, 421-427.	2.8	7
20	Rapid decrease in serum VEGF-A levels may be a worse prognostic biomarker for patients with platinum-resistant recurrent ovarian cancer treated with bevacizumab and gemcitabine. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 941-947.	2.3	5
21	A case of spontaneous ovarian hyperstimulation syndrome after vaginal delivery. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 1022-1024.	0.9	2
22	A multi-center retrospective study of neuroendocrine tumors of the uterine cervix: Prognosis according to the new 2018 staging system, comparing outcomes for different chemotherapeutic regimens and histopathological subtypes. <i>Gynecologic Oncology</i> , 2019, 155, 444-451.	1.4	36
23	Significant relationship between the LAT1 expression pattern and chemoresistance in ovarian clear cell carcinoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 701-710.	2.8	18
24	Response to correspondence "Prophylactic use of Bakri balloon for placenta previa surgery: A simple procedure to prevent balloon prolapse". <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2019, 58, 440.	1.3	1
25	Thrombotic events induce the worse prognosis in ovarian carcinomas and frequently develop in ovarian clear cell carcinoma. <i>International Journal of Clinical Oncology</i> , 2019, 24, 1273-1283.	2.2	14
26	Pretreatment Neutrophil-to-Lymphocyte Ratio Was a Predictor of Lymph Node Metastasis in Endometrial Cancer Patients. <i>Oncology</i> , 2019, 96, 259-267.	1.9	34
27	Analysis of prophylactic Bakri balloon tamponade failure in patients with placenta previa. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2019, 58, 159-163.	1.3	13
28	A rare case of Coombs-negative autoimmune haemolytic anaemia in pregnancy. <i>Journal of Obstetrics and Gynaecology</i> , 2019, 39, 541-542.	0.9	0
29	Addition of bevacizumab to gemcitabine for platinum-resistant recurrent ovarian cancer: a retrospective analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 809-814.	2.3	7
30	Ovarian cancer therapeutic potential of glutamine depletion based on GS expression. <i>Carcinogenesis</i> , 2018, 39, 758-766.	2.8	29
31	JAK2/STAT3 pathway as a therapeutic target in ovarian cancers. <i>Oncology Letters</i> , 2018, 15, 5772-5780.	1.8	38
32	A case of refeeding syndrome in pregnancy with anorexia nervosa. <i>Obstetric Medicine</i> , 2018, 11, 95-97.	1.1	5
33	Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 81, 111-117.	2.3	9
34	Seromucinous component in endometrioid endometrial carcinoma as a histological predictor of prognosis. <i>Journal of Gynecologic Oncology</i> , 2018, 29, e20.	2.2	7
35	Pregnancy with "mimicking placenta previa and large cervical leiomyoma" caused by incarcerated retroverted uterus. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2018, 57, 616-617.	1.3	3
36	Small Foci of Serous Component as a Predictor of Recurrence and Prognosis for Stage IA Endometrial Carcinomas. <i>Oncology</i> , 2017, 93, 29-35.	1.9	3

#	ARTICLE	IF	CITATIONS
37	Multiple placental surface cysts with intracystic hemorrhaging: A case report and review of the literature. <i>Journal of Obstetrics and Gynaecology Research</i> , 2017, 43, 1346-1349.	1.3	2
38	Pregnancy with asymptomatic uterine complete rupture after uterine artery embolization for postpartum hemorrhage. <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2017, 56, 538-540.	1.3	6
39	Cervical varicosities may predict placenta accreta in posterior placenta previa: a magnetic resonance imaging study. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 731-736.	1.7	9
40	Ovarian serous carcinomas acquire cisplatin resistance and increased invasion through downregulation of the high-temperature-required protein A2 (HtrA2), following repeated treatment with cisplatin. <i>Medical Oncology</i> , 2017, 34, 201.	2.5	7
41	Effect of routine rapid insertion of Bakri balloon tamponade on reducing hemorrhage from placenta previa during and after cesarean section. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 469-474.	1.7	25
42	Response to Correspondence "Asymptomatic uterine rupture detected at cesarean section: Some different viewpoints". <i>Taiwanese Journal of Obstetrics and Gynecology</i> , 2017, 56, 872.	1.3	0
43	Role of endometriosis as a prognostic factor for postoperative progression survival in ovarian clear cell carcinoma. <i>Molecular and Clinical Oncology</i> , 2017, 7, 1027-1031.	1.0	6
44	UGT1A1 polymorphisms in cancer: impact on irinotecan treatment. <i>Pharmacogenomics and Personalized Medicine</i> , 2017, Volume10, 61-68.	0.7	53
45	Inhibition of autophagy protein LC3A as a therapeutic target in ovarian clear cell carcinomas. <i>Journal of Gynecologic Oncology</i> , 2017, 28, e33.	2.2	14
46	Combination of irinotecan and platinum for platinum-resistant or refractory recurrent ovarian cancers: A preliminary case series. <i>Molecular and Clinical Oncology</i> , 2017, 7, 51-55.	1.0	1
47	Analysis of the effect of adjuvant radiotherapy on outcomes and complications after radical hysterectomy in FIGO stage IB1 cervical cancer patients with intermediate risk factors (GOTIC Study). <i>World Journal of Surgical Oncology</i> , 2016, 14, 173.	1.9	28
48	Relation between Birth Weight and Intraoperative Hemorrhage during Cesarean Section in Pregnancy with Placenta Previa. <i>PLoS ONE</i> , 2016, 11, e0167332.	2.5	5
49	Impact of UGT1A1 genotype upon toxicities of combination with low-dose irinotecan plus platinum. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2016, 12, 115-124.	1.1	12
50	Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. <i>European Journal of Cancer</i> , 2016, 64, 22-31.	2.8	180
51	Immunocytochemical utility of claudin-4 versus those of Ber-EP4 and MOC-31 in effusion cytology. <i>Diagnostic Cytopathology</i> , 2016, 44, 499-504.	1.0	23
52	DNA mismatch repair-related protein loss as a prognostic factor in endometrial cancers. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 40.	2.2	76
53	Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. <i>Journal of Clinical Oncology</i> , 2015, 33, 2129-2135.	1.6	291
54	Administration of standard-dose BEP regimen (bleomycin+etoposide+cisplatin) is essential for treatment of ovarian yolk sac tumour. <i>European Journal of Cancer</i> , 2015, 51, 340-351.	2.8	23

#	ARTICLE	IF	CITATIONS
55	Clinical tumor diameter and prognosis of patients with FIGO stage IB1 cervical cancer (JCOG0806-A). <i>Gynecologic Oncology</i> , 2015, 137, 34-39.	1.4	77
56	A non-randomized confirmatory study regarding selection of fertility-sparing surgery for patients with epithelial ovarian cancer: Japan Clinical Oncology Group Study (JCOG1203). <i>Japanese Journal of Clinical Oncology</i> , 2015, 45, 595-599.	1.3	17
57	High Expression of p62 Protein Is Associated with Poor Prognosis and Aggressive Phenotypes in Endometrial Cancer. <i>American Journal of Pathology</i> , 2015, 185, 2523-2533.	3.8	42
58	Combination therapy with temsirolimus and trabectedin for recurrent clear cell carcinoma of the ovary: A phase II study with biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5583-5583.	1.6	3
59	Synergistic effects of cabozantinib to temozolomide and bevacizumab in patients with heavily pretreated relapsed uterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5590-5590.	1.6	6
60	Weekly administration of bevacizumab, eribulin, and oxaliplatin in patients with platinum-resistant ovarian carcinomas: A phase II study with biomarker analysis.. <i>Journal of Clinical Oncology</i> , 2015, 33, 5603-5603.	1.6	0
61	Gynecologic Cancer InterGroup (GCIg) Consensus Review for Clear Cell Carcinoma of the Ovary. <i>International Journal of Gynecological Cancer</i> , 2014, 24, S20-S25.	2.5	116
62	Efficacy and safety of triple therapy with aprepitant, palonosetron, and dexamethasone for preventing nausea and vomiting induced by cisplatin-based chemotherapy for gynecological cancer: KCOG-G1003 phase II trial. <i>Supportive Care in Cancer</i> , 2014, 22, 2891-2898.	2.2	8
63	High Expression of SQSTM1/p62 Protein Is Associated with Poor Prognosis in Epithelial Ovarian Cancer. <i>Acta Histochemica Et Cytochemica</i> , 2014, 47, 295-301.	1.6	44
64	Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in phase III randomized trial: JCOG0602.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5508-5508.	1.6	6
65	Combination chemotherapy with temsirolimus and trabectedin for recurrent clear cell carcinoma of the ovary: A phase II single arm clinical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5517-5517.	1.6	3
66	Weekly administration of bevacizumab, eribulin, and oxaliplatin in patients with platinum-resistant and refractory ovarian carcinomas: A phase II study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5566-5566.	1.6	1
67	Effects of temozolomide and bevacizumab in patients with pretreated relapsed uterine leiomyosarcoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 5603-5603.	1.6	0
68	Short response duration even in responders to chemotherapy using conventional cytotoxic agents in recurrent or refractory clear cell carcinomas of the ovary. <i>International Journal of Clinical Oncology</i> , 2013, 18, 556-557.	2.2	8
69	Complete remission of recurrent ovarian clear cell carcinoma by chemotherapy with bevacizumab, trabectedin and oxaliplatin. <i>Journal of Obstetrics and Gynaecology Research</i> , 2013, 39, 872-875.	1.3	11
70	Clear cell histology as a poor prognostic factor for advanced epithelial ovarian cancer: a single institutional case series through central pathologic review. <i>Journal of Gynecologic Oncology</i> , 2013, 24, 37.	2.2	38
71	Beyond the bevacizumab resistance, combined effects of erlotinib in heavily pretreated patients with recurrent ovarian cancers.. <i>Journal of Clinical Oncology</i> , 2013, 31, e16505-e16505.	1.6	0
72	Effect of weekly administration of bevacizumab, eribulin, and oxaliplatin in patients with heavily pretreated serous ovarian carcinoma.. <i>Journal of Clinical Oncology</i> , 2013, 31, e16506-e16506.	1.6	2

#	ARTICLE	IF	CITATIONS
73	Effects of temozolomide combined with bevacizumab in patients with relapsed uterine sarcoma.. Journal of Clinical Oncology, 2013, 31, e21520-e21520.	1.6	0
74	Evaluation of UGT1A1 genotyping for predicting individual toxicity of irinotecan plus platinum analog regimens: Interim safety analysis of a prospective observational study.. Journal of Clinical Oncology, 2013, 31, 11049-11049.	1.6	0
75	Gene scoring model to predict recurrence in low- and intermediate-risk uterine endometrial cancer: Establishment of uterine print.. Journal of Clinical Oncology, 2013, 31, 5590-5590.	1.6	0
76	Aberrant Expression of the Mammalian Target of Rapamycin, Hypoxia-inducible Factor-1 $\alpha$ , and Glucose Transporter 1 in the Development of Ovarian Clear-cell Adenocarcinoma. International Journal of Gynecological Pathology, 2012, 31, 254-263.	1.4	15
77	Clear cell carcinoma of the ovary: Is there a role of histology-specific treatment?. Journal of Experimental and Clinical Cancer Research, 2012, 31, 53.	8.6	72
78	A randomized, phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group study (JCOG0505).. Journal of Clinical Oncology, 2012, 30, 5006-5006.	1.6	31
79	Effect of weekly administration of bevacizumab, gemcitabine, and oxaliplatin in patients with heavily pretreated ovarian cancer.. Journal of Clinical Oncology, 2012, 30, 5037-5037.	1.6	1
80	Effects of weekly bevacizumab and gemcitabine/oxaliplatin with or without dasatinib on heavily pretreated patients with recurrent or persistent cervical cancer.. Journal of Clinical Oncology, 2012, 30, e15579-e15579.	1.6	1
81	Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers. Gynecologic Oncology, 2011, 122, 233-237.	1.4	53
82	Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases. International Journal of Clinical Oncology, 2011, 16, 605-609.	2.2	40
83	Randomized Phase II Trial of Paclitaxel Plus Carboplatin Therapy Versus Irinotecan Plus Cisplatin Therapy as First-Line Chemotherapy for Clear Cell Adenocarcinoma of the Ovary. International Journal of Gynecological Cancer, 2010, 20, 240-247.	2.5	55
84	Identification of potential serum markers for endometrial cancer using protein expression profiling. Journal of Cancer Research and Clinical Oncology, 2010, 136, 475-481.	2.5	18
85	Indispensability of UGT1A1*6 genotyping in Japanese cancer patients treated with irinotecan. International Journal of Clinical Oncology, 2010, 15, 224-225.	2.2	1
86	Outcomes of Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer: A Proposal for Patient Selection. Journal of Clinical Oncology, 2010, 28, 1727-1732.	1.6	171
87	Less impact of adjuvant chemotherapy for stage I clear cell carcinoma of the ovary: a retrospective Japan Clear Cell Carcinoma Study. International Journal of Gynecological Cancer, 2010, 20, 1506-10.	2.5	42
88	Clinical Significance of UDP-Glucuronosyltransferase 1A1*6 for Toxicities of Combination Chemotherapy with Irinotecan and Cisplatin in Gynecologic Cancers. Oncology, 2009, 76, 315-321.	1.9	56
89	Complete Remission of Metastatic and Relapsed Uterine Cervical Cancers Using Weekly Administration of Bevacizumab and Paclitaxel/Carboplatin. Onkologie, 2009, 32, 595-597.	0.8	7
90	The Impact of Complete Surgical Staging Upon Survival in Early-Stage Ovarian Clear Cell Carcinoma. International Journal of Gynecological Cancer, 2009, 19, 1353-1357.	2.5	35

#	ARTICLE	IF	CITATIONS
91	Survival analysis of ovarian clear cell carcinoma confined to the ovary with or without comprehensive surgical staging. <i>Oncology Reports</i> , 2008, 19, 1259-64.	2.6	6
92	Actinin-4 expression in ovarian cancer: a novel prognostic indicator independent of clinical stage and histological type. <i>Modern Pathology</i> , 2007, 20, 1278-1285.	5.5	73
93	Progression-free survival and overall survival of patients with clear cell carcinoma of the ovary treated with paclitaxel-carboplatin or irinotecan-cisplatin: retrospective analysis. <i>International Journal of Clinical Oncology</i> , 2007, 12, 256-260.	2.2	33
94	Adjuvant chemotherapy with irinotecan hydrochloride and cisplatin for clear cell carcinoma of the ovary. <i>Oncology Reports</i> , 2006, 16, 1301-6.	2.6	32
95	Treatment options in the management of ovarian cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2005, 6, 743-754.	1.8	19
96	Abstract of Poster Presentation. <i>Human Cell</i> , 2005, 18, 43-65.	2.7	0
97	Amplicon profiling reveals cytoplasmic overexpression of MUC1 protein as an indicator of resistance to platinum-based chemotherapy in patients with ovarian cancer. <i>Oncology Reports</i> , 2004, 12, 1177-82.	2.6	11
98	Successful management of cervical pregnancy by selective uterine artery embolization: a case report. <i>Journal of reproductive medicine, The</i> , 2004, 49, 986-8.	0.2	10
99	Malignant mixed Mullerian tumor of the uterine corpus with alpha-fetoprotein-producing hepatoid adenocarcinoma component. <i>Gynecologic Oncology</i> , 2003, 91, 444-448.	1.4	27
100	Phase I and pharmacological study of single paclitaxel administered weekly for heavily pre-treated patients with epithelial ovarian cancer. <i>Anticancer Research</i> , 2002, 22, 1833-8.	1.1	5
101	Presence of Multiple HIV Type 1 Subtypes among Mothers and Children in Japan. <i>AIDS Research and Human Retroviruses</i> , 2001, 17, 569-575.	1.1	7
102	Embryonal Rhabdomyosarcoma of the Uterine Corpus in a 76-Year-Old Patient. <i>Gynecologic Oncology</i> , 1999, 75, 490-494.	1.4	16